KC 706

Drug Profile

KC 706

Alternative Names: KC706

Latest Information Update: 08 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kemia
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipidaemia; Pemphigus vulgaris; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 08 Oct 2014 Discontinued - Phase-II for Hyperlipidaemia in Europe (PO)
  • 08 Oct 2014 Discontinued - Phase-II for Pemphigus in USA (PO)
  • 08 Oct 2014 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top